XILIO THERAPEUTICS INC (XLO) Stock Analyst Earnings Estimates
NASDAQ:XLO - Nasdaq - US98422T1007 - Common Stock - Currency: USD
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A 368.33% | N/A -9.89% | N/A -84.62% | N/A | N/A 527.50% | N/A 349.75% | ||||||
| EBITDA YoY % growth | -18.79M | -53.49M -184.67% | -73.54M -37.48% | -87.3M -18.71% | -77.233M 11.53% | N/A 18.97% | N/A 49.28% | N/A -136.30% | N/A -50.84% | N/A -13.37% | N/A 15.60% | N/A 137.10% | |
| EBIT YoY % growth | -19.03M | -54.56M -186.71% | -75.04M -37.54% | -89.15M -18.80% | -79.133M 11.24% | N/A 21.28% | N/A 30.76% | N/A -49.04% | N/A -118.96% | N/A -26.90% | N/A -8.82% | N/A 50.91% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | N/A | -3.22 48.63% | -2.78 13.66% | N/A 58.58% | N/A 55.53% | N/A 11.05% | N/A -166.08% | N/A 60.00% | N/A 176.04% | N/A 198.63% |
All data in USD
| Q4 / 24 | Q1 / 25 | Q2 / 25 | Q3 / 25 | Q4 / 25 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.23 64.76% | -0.14 78.01% | -0.14 41.08% | -0.16 28.84% | 0.01 102.24% |
| Revenue Q2Q % growth | 3.333M | 2.929M | 2.929M 24.27% | 2.929M 29.43% | 40.804M 1,124.24% |
| EBITDA Q2Q % growth | -17.17M -5.79% | -18.18M -12.95% | -19.19M -39.20% | -20.2M -49.25% | 55.166M 421.29% |
| EBIT Q2Q % growth | -14.458M 20.25% | -16.251M 1.74% | -17.337M -18.15% | -18.422M -24.45% | 18.367M 227.04% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2024 Q2Q % growth | -0.22 63.93% | -0.25 | 0.03 | 11.70% |
| Q2 2024 Q2Q % growth | -0.24 65.71% | -0.23 | -0.01 | -3.31% |
| Q1 2024 Q2Q % growth | -0.62 25.30% | -0.11 | -0.51 | -458.06% |
| Q4 2023 Q2Q % growth | -0.64 21.95% | -0.65 | 0.01 | 0.99% |
| Q3 2023 Q2Q % growth | -0.61 15.28% | -0.82 | 0.21 | 25.21% |
| Q2 2023 Q2Q % growth | -0.70 22.22% | -0.88 | 0.18 | 20.11% |
| Q1 2023 Q2Q % growth | -0.83 -6.41% | -0.89 | 0.06 | 7.22% |
| Q4 2022 Q2Q % growth | -0.82 16.33% | -0.79 | -0.03 | -3.42% |
| Q3 2022 Q2Q % growth | -0.72 96.61% | -0.89 | 0.17 | 18.76% |
| Q2 2022 Q2Q % growth | -0.90 | -0.79 | -0.11 | -14.10% |
| Q1 2022 Q2Q % growth | -0.78 | -0.94 | 0.16 | 16.80% |
| Q4 2021 Q2Q % growth | -0.98 | -1.18 | 0.20 | 16.80% |
| Q3 2021 Q2Q % growth | -21.27 | -1.61 | -19.66 | -1,218.27% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2024 Q2Q % growth | 2.263M | 3.333M | -1.07M | -32.10% |
| Q2 2024 Q2Q % growth | 2.357M | 30.3M | -27.943M | -92.22% |
| Q1 2024 Q2Q % growth | 30.3M | -30.3M | -100.00% |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 0% | 12.99% | 0% | 9.28% |
| Revenue | 0% | 0% | 0.09% | 24.37% |